Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20050101582 A1
Publication typeApplication
Application numberUS 10/966,764
Publication dateMay 12, 2005
Filing dateOct 14, 2004
Priority dateNov 12, 2003
Also published asCA2545878A1, CA2545878C, CN105748407A, DE602004019801D1, DE602004027773D1, EP1682185A2, EP1682185B1, EP1997497A2, EP1997497A3, EP1997497B1, US8569272, US9265775, US20080269181, US20140051671, WO2005046641A2, WO2005046641A3
Publication number10966764, 966764, US 2005/0101582 A1, US 2005/101582 A1, US 20050101582 A1, US 20050101582A1, US 2005101582 A1, US 2005101582A1, US-A1-20050101582, US-A1-2005101582, US2005/0101582A1, US2005/101582A1, US20050101582 A1, US20050101582A1, US2005101582 A1, US2005101582A1
InventorsRobert Lyons, James Chang, John Trogden, Scott Whitcup
Original AssigneeAllergan, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Compositions and methods for treating a posterior segment of an eye
US 20050101582 A1
Abstract
Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.
Images(10)
Previous page
Next page
Claims(62)
1. A composition useful for injection into a posterior segment of an eye of a human or animal comprising:
a corticosteroid component present in a therapeutically effective amount, the corticosteroid component being present in a plurality of particles;
a viscosity inducing component in an amount effective in increasing the viscosity of the composition; and
an aqueous carrier component, the composition having a viscosity of at least about 10 cps at a shear rate of 0.1/second and being effectively injectable into a posterior segment of an eye of a human or animal.
2. The composition of claim 1 which has a viscosity of at least 100 cps at a shear rate of 0.1/second.
3. The composition of claim 1 which has a viscosity of at least 10,000 cps at a shear rate of 0.1/second.
4. The composition of claim 1 which has a viscosity of from about 140,000 cps—about 300,000 cps at a shear rate of 0.1/second.
5. The composition of claim 1 which is effectively injectable through a 27 gauge needle into a posterior segment of an eye of a human or animal.
6. The composition of claim 1 which is effectively injectable through a 30 gauge needle into a posterior segment of an eye of a human or animal.
7. The composition of claim 1 wherein the particles are substantially uniformly suspended in the composition.
8. The composition of claim 7 wherein the particles remain substantially uniformly suspended in the composition for at least about 1 week without requiring resuspension processing.
9. The composition of claim 7 wherein the particles remain substantially uniformly suspended in the composition for at least about 1 month without requiring resuspension processing.
10. The composition of claim 7 wherein the particles remain substantially uniformly suspended in the composition for at least about 6 months without requiring resuspension processing.
11. The composition of claim 7 wherein the particles remain substantially uniformly suspended in the composition for at least about 1 year without requiring resuspension processing.
12. The composition of claim 7 wherein the particles remain substantially uniformly suspended in the composition for at least about 2 years without requiring resuspension processing.
13. The composition of claim 1 wherein the corticosteroid component is present in an amount of up to about 25% (w/v) of the composition.
14. The composition of claim 1 wherein the corticosteroid component is present in an amount of at least about 10 mg per ml of composition.
15. The composition of claim 1 wherein the corticosteroid component is present in an amount in a range of about 1% to about 20% (w/v) of the composition.
16. The composition of claim 1 wherein the corticosteroid component is present in an amount in a range of about 1% to about 10% (w/v) of the composition.
17. The composition of claim 1 wherein the corticosteroid component has a solubility in water at 25° C. of less than 10 mg/ml.
18. The composition of claim 1 wherein the corticosteroid component is selected from the group consisting of cortisone, prednisolone, triamcinolone, fluorometholone, dexamethasone, medrysone, loteprednol, derivatives thereof and mixtures thereof.
19. The composition of claim 1 wherein the corticosteroid component is triamcinolone acetonide.
20. The composition of claim 1 wherein the carrier component includes an effective amount of at least one of a preservative component, a tonicity component and a buffer component.
21. The composition of claim 1 which includes no added preservative component.
22. The composition of claim 1 which includes no added resuspension component.
23. The composition of claim 1 wherein the viscosity inducing component is present in an amount in a range of about 0.05% to about 20% (w/v) of the composition.
24. The composition of claim 1 wherein the viscosity inducing component comprises a polymeric component.
25. The composition of claim 1 wherein the viscosity inducing component comprises at least one viscoelastic agent.
26. The composition of claim 1 wherein the viscosity inducing component is selected from the group consisting of polymeric hyaluronic acid, carbomers, polyacrylic acid, cellulosic derivatives, polycarbophil, polyvinylpyrrolidone, gelatin, dextrin, polysaccharides, polyacrylamide, polyvinyl alcohol, polyvinyl acetate, derivatives thereof and mixtures thereof.
27. The composition of claim 1 wherein the viscosity inducing component comprises a hyaluronate component.
28. The composition of claim 27 wherein the hyaluronate component comprises sodium hyaluronate.
29. A method of treatment comprising administering the composition of claim 1 to a posterior segment of an eye of a human or animal, thereby obtaining a desired therapeutic effect.
30. The method of claim 29 wherein the administering step comprises intravitreal injecting.
31. The method of claim 29 wherein the administering step comprises subconjunctival injecting.
32. The method of claim 29 wherein the administering step comprises sub-tenon injecting.
33. The method of claim 29 wherein the administering step comprises retrobulbar injecting.
34. The method of claim 29 wherein the administering step comprises suprachoroidal injecting.
35. A composition useful for injection into a posterior segment of an eye of a human or animal comprising:
a corticosteroid component present in a therapeutic effect amount, the corticosteroid component being present in a plurality of particles;
a viscosity inducing component in an amount effective in increasing the viscosity of the composition; and
an aqueous carrier component, the particles being substantially uniformly suspended in the composition and remaining substantially uniformly suspended in the composition for at least about 1 week without requiring resuspension processing.
36. The composition of claim 35 wherein the particles remain substantially uniformly suspended in the composition for at least about 2 weeks without requiring resuspension processing.
37. The composition of claim 35 wherein the particles remain substantially uniformly suspended in the composition for at least about 1 month without requiring resuspension processing.
38. The composition of claim 35 wherein the particles remain substantially uniformly suspended in the composition for at least about 6 months without requiring resuspension processing.
39. The composition of claim 35 wherein the particles remain substantially uniformly suspended in the composition for at least about 1 year without requiring resuspension processing.
40. The composition of claim 35 wherein the particles remain substantially uniformly suspended in the composition for at least about 2 years without requiring resuspension processing.
41. The composition of claim 35 wherein the corticosteroid component is present in an amount of up to about 25% (w/v) of the composition.
42. The composition of claim 35 wherein the corticosteroid component is present in an amount of at least about 10 mg per ml of composition.
43. The composition of claim 35 wherein the corticosteroid component is present in an amount in a range of about 1% to about 20% (w/v) of the composition.
44. The composition of claim 35 wherein the corticosteroid component is present in an amount in a range of about 1% to about 10% (w/v) of the composition.
45. The composition of claim 35 wherein the corticosteroid component has a solubility in water at 25° C. of less than 10 mg/ml.
46. The composition of claim 35 wherein the corticosteroid component is selected from the group consisting of cortisone, prednisolone, triamcinolone, fluorometholone, dexamethasone, medrysone, loteprednol, derivatives thereof and mixtures thereof.
47. The composition of claim 35 wherein the corticosteroid component is triamcinolone acetonide.
48. The composition of claim 35 wherein the carrier component includes an effective amount of at least one of a preservative component, a tonicity component and a buffer component.
49. The composition of claim 35 which includes no added preservative component.
50. The composition of claim 35 which includes no added resuspension component.
51. The composition of claim 35 wherein the viscosity inducing component is present in an amount in a range of about 0.05% to about 20% (w/v) of the composition.
52. The composition of claim 35 wherein the viscosity inducing component comprises a polymeric component.
53. The composition of claim 35 wherein the viscosity inducing component comprises at least one viscoelastic agent.
54. The composition of claim 35 wherein the viscosity inducing component is selected from the group consisting of polymeric hyaluronic acid, carbomers, polyacrylic acid, cellulosic derivatives, polycarbophil, polyvinylpyrrolidone, gelatin, dextrin, polysaccharides, polyacrylamide, polyvinyl alcohol, polyvinyl acetate, derivatives thereof and mixtures thereof.
55. The composition of claim 35 wherein the viscosity inducing component comprises a hyaluronate component.
56. The composition of claim 55 wherein the hyaluronate component comprises sodium hyaluronate.
57. A method of treatment comprising administering the composition of claim 35 to a posterior segment of an eye of a human or animal, thereby obtaining a desired therapeutic effect.
58. The method of claim 57 wherein the administering step comprises intravitreal injecting.
59. The method of claim 57 wherein the administering step comprises subconjunctival injecting.
60. The method of claim 57 wherein the administering step comprises sub-tenon injecting.
61. The method of claim 57 wherein the administering step comprises retrobulbar injecting.
62. The method of claim 57 wherein the administering step comprises suprachoroidal injecting.
Description
    RELATED APPLICATIONS
  • [0001]
    This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/519,237, filed Nov. 12, 2003 and U.S. Provisional Patent Application Ser. No. 60/530,062, filed Dec. 16, 2003, which are hereby incorporated by reference in their entireties.
  • [0002]
    This invention relates to compositions and methods for treating posterior segments of eyes of humans or animals. More particularly, the invention relates to compositions including corticosteroid components which can be effectively injected into posterior segments of such eyes and to methods of using such compositions to provide desired therapeutic effects.
  • [0003]
    Among the therapies currently being practiced to treat ocular posterior segment disorders, such as uveitis, macular degeneration, macular edema and the like, is intravitreal injection of a corticosteroid, such as triamcinolone acetonide (TA). See, for example, Billson et al U.S. Pat. No. 5,770,589, the disclosure of which is incorporated in its entirety herein by reference.
  • [0004]
    One medication commonly employed for this ophthalmic therapy is Kenalog® 40. Each milliliter (ml) of the Kenalog® 40 composition includes 40 milligrams (mg) of TA, sodium chloride as a tonicity agent, 10 mg of benzyl alcohol as a preservative, and 7.5 mg of carboxymethylcellulose and 0.4 mg of polysorbate 80 as resuspension aids. Although widely used by ophthalmologists, this commercially available formulation suffers from several important limitations.
  • [0005]
    For example, the presence of benzyl alcohol preservative and polysorbate 80 surfactant tends to lead to unnecessary and/or undue cell damage or other toxicities in sensitive ocular tissues. Even though some clinicians routinely “wash” the TA precipitate several times with saline to reduce the concentration of these undesirable materials, such washing is inconvenient, time consuming, and most importantly, increases the probability of microbial or endotoxin contamination that could lead to intraocular infection and inflammation.
  • [0006]
    Moreover, the TA in the Kenalog® 40 tends to rapidly separate and precipitate from the remainder of the composition. For example, this composition, if left standing for 1 to 2 hours, results in a substantial separation of a TA precipitate from the remainder of the composition. Thus, if the composition is to be injected into the eye, it must be vigorously shaken and used promptly after being so shaken in order to provide a substantially uniform suspension in the eye. In addition, resuspension processing requires the use of the resuspension aids noted above, at least one of which is less than totally desirable for sensitive ocular tissues.
  • [0007]
    There is a need for new compositions for injection into the posterior segments of eyes of humans or animals and methods for providing desired therapeutic effects in the posterior segments of eyes of humans or animals.
  • SUMMARY OF THE INVENTION
  • [0008]
    New compositions and methods for treating posterior segments of eyes of humans or animals have been discovered. The present compositions are highly suitable for intravitreal administration into the posterior segments of eyes without requiring any “washing step”, while providing for reduced ocular, for example, retinal, damage when used in an eye. The present compositions are advantageously substantially free of added preservative components, for example, contain no benzyl alcohol preservative. In addition, the present compositions advantageously require no resuspension aid or aids. Overall, the present compositions are easily and effectively injectable into the posterior segment of an eye of a human or animal and can be maintained as a substantially uniform suspension for long periods of time, for example, at least about one week or more, without resuspension processing, for example, without requiring shaking or other agitating of the composition to obtain substantial suspension uniformity. In short, the present compositions and methods provide substantial enhancements and advantages, for example, relative to the prior art Kenalog® 40 composition and methods of using such prior art composition, in the posterior segments of human or animal eyes.
  • [0009]
    In one broad aspect of the present invention, compositions useful for injection into a posterior segment of an eye of a human or animal are provided. Such compositions comprise a corticosteroid component, a viscosity inducing component, and an aqueous carrier component. The corticosteroid component is present in a therapeutically effective amount. The corticosteroid component is present in the compositions in a plurality of particles.
  • [0010]
    The present compositions may include a corticosteroid component in an amount of up to about 25% (w/v) or more of the composition. In one very useful embodiment, the corticosteroid component is present in an amount of at least about 80 mg/ml of composition. Preferably, the corticosteroid component is present in an amount in a range of about 1% to about 10% or about 20% (w/v) of the composition.
  • [0011]
    In one very useful embodiment, the corticosteroid component comprises triamcinolone acetonide.
  • [0012]
    The viscosity inducing component is present in an amount effective in increasing the viscosity of the composition.
  • [0013]
    Any suitable, preferably ophthalmically acceptable, viscosity inducing component may be employed in accordance with the present invention. Many such viscosity inducing components have been proposed and/or used in ophthalmic compositions used on or in the eye. Advantageously, the viscosity inducing component is present in an amount in a range of about 0.5% to about 20% (w/v) of the composition. In one particularly useful embodiment, the viscosity inducing component is a hyaluronic acid polymer component, such as sodium hyaluronate.
  • [0014]
    In one embodiment, the present compositions have a viscosity of at least about 10 cps or at least about 100 cps, preferably at least about 1,000 cps, more preferably at least about 10,000 cps and still more preferably at least about 70,000 cps, for example, up to about 250,000 cps, or about 300,000 cps, at a shear rate of 0.1/second. The present compositions are structured or have make-ups so as to be effectively, for example, manually, injected into a posterior segment of an eye of a human or animal, preferably through a 27 gauge needle, more preferably through a 29 or 30 gauge needle.
  • [0015]
    Without wishing to limit the invention to any particular theory of operation, it is believed that the use of relatively high viscosity compositions, as described herein, provides for effective, and preferably substantially uniform, suspension of the steroid component particles while, at the same time, being injectable into the posterior segment of an eye through conventionally, or even smaller than conventionally, used needles.
  • [0016]
    In one embodiment of the invention, the corticosteroid component is present in a plurality of particles which are substantially uniformly suspended in the composition and remain substantially uniformly suspended in the composition for at least about 1 week, preferably at least about 2 weeks or at least about 1 month, and still more preferably at least about 6 months or at least about 1 year or at least about 2 years, without requiring resuspension processing, that is, without requiring being shaken or otherwise agitated to maintain the corticosteroid component particles substantially uniformly suspended in the composition.
  • [0017]
    Compositions having such substantially uniform suspension of corticosteroid component particles provide substantial advantages relative to the prior art. In particular, the present compositions may be manufactured, shipped and stored for substantial periods of time without the corticosteroid component particles precipitating from the remainder of the composition. Having the corticosteroid component particles maintained substantially uniformly suspended in the composition allows the composition to be quickly and effectively used to provide treatment to the posterior segment of an eye of a human or animal without concern for having to resuspend such particles.
  • [0018]
    The aqueous carrier component is advantageously ophthalmically acceptable and may include one or more conventional expedients useful in ophthalmic compositions.
  • [0019]
    For example, the carrier component may include an effective amount of at least one of a preservative component, a tonicity component and a buffer component.
  • [0020]
    In one advantageous embodiment, the present compositions include no added preservative component. This feature reduces or minimizes or even substantially eliminates adverse reactions in the eye which may be caused by or linked to the presence of a preservative component.
  • [0021]
    Although a resuspension component may be employed in accordance with the present invention, in many instances, because of the ability of the present composition to remain a substantially uniform suspension for a long period of time without requiring resuspension processing, the compositions advantageously contain no added resuspension components.
  • [0022]
    Methods of treating posterior segments of the eyes of humans or animals are also disclosed and are included within the scope of the present invention. In general, such methods comprise administering, e.g. injecting a corticosteroid component-containing composition, for example, a composition in accordance with the present intention, to a posterior segment of an eye of a human or animal. Such administering is effective in providing a desired therapeutic effect. The administering step advantageously comprises at least one of intravitreal injecting, subconjunctival injecting, sub-tenon injecting, retrobulbar injecting, suprachoroidal injecting and the like.
  • [0023]
    Each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present invention provided that the features included in such a combination are not mutually inconsistent.
  • [0024]
    These and other aspects and advantages of the present invention are apparent in the following detailed description, examples and claims.
  • DETAILED DESCRIPTION
  • [0025]
    The present invention involves compositions useful for placement, preferably by injection, into a posterior segment of an eye of a human or animal. Such compositions in the posterior, e.g., vitreous, of the eye are therapeutically effective against one or more conditions and/or diseases of the posterior of the eye, and/or one or more symptoms of such conditions and/or diseases of the posterior of the eye.
  • [0026]
    In general, the present compositions comprise a corticosteroid component; a viscosity inducing component; and an aqueous carrier component. The compositions are advantageously ophthalmically acceptable.
  • [0027]
    One of the important advantages of the present compositions is that they are more compatible with or friendly to the tissues in the posterior segment of the eye, for example, the retina of the eye, relative to compositions previously proposed for intravitreal injection into a posterior segment of an eye, for example, a composition sold under the trademark Kenalog®-40. In particular, the present compositions advantageously are substantially free of added preservative components or include effective preservative components which are more compatible with or friendly to the posterior segment, e.g., retina, of the eye relative to benzyl alcohol, which is included in the Kenalog®-40 composition as a preservative.
  • [0028]
    In addition, the present compositions preferably include no added resuspension component or a resuspension component which is more compatible with or friendly to the posterior segment, e.g., retina, of the eye relative to polysorbate-80, which is included in the Kenalog®-40 composition. Many of the other features of the present compositions, as described elsewhere herein, also render the present compositions more compatible with or friendly to the posterior segments of the eyes into which the compositions are placed relative to prior art compositions, such as Kenalog®-40.
  • [0029]
    As noted above, the present compositions include a corticosteroid component. Such corticosteroid component is present in the compositions in a therapeutically effective amount, that is in an amount effective in providing a desired therapeutic effect in the eye into which the composition is placed. The corticosteroid component is present in the composition in a plurality of particles.
  • [0030]
    Any suitable corticosteroid component may be employed in according to the present invention. Such corticosteroid component advantageously has a limited solubility in water, for example, at 25° C. For example, the corticosteroid component preferably has a solubility in water at 25° C. of less than 10 mg/ml. Of course, the corticosteroid component should be ophthalmically acceptable, that is, should have substantially no significant or undue detrimental effect of the eye structures or tissues. One particularly useful characteristic of the presently useful corticosteroid components is the ability of such component to reduce inflammation in the posterior segment of the eye into which the composition is placed caused by the result of one or more diseases and/or conditions in the posterior segment of the eye.
  • [0031]
    Examples of useful corticosteroid components include, without limitation, cortisone, prednesolone, triamcinolone, triamcinolone acetonide, fluorometholone, dexamethosone, medrysone, loteprednol, derivatives thereof and mixtures thereof. As used herein, the term “derivative” refers to any substance which is sufficiently structurally similar to the material of which it is identified as a derivative so as to have substantially similar functionality or activity, for example, therapeutic effectiveness, as the material when the substance is used in place of the material.
  • [0032]
    In one very useful embodiment, the corticosteroid component comprises triamcinolone acetonide.
  • [0033]
    The corticosteroid component advantageously is present in an amount of at least about 10 mg per ml of the composition. One important advantage of the present invention is the effective ability of the present compositions to include relatively large amounts or concentrations of the corticosteroid component. Thus, the corticosteroid component may be present in the present compositions in an amount in the range of about 1% or less to about 5% or about 10% or about 20% or about 30% or more (w/v) of the composition. Providing relatively high concentrations or amounts of corticosteroid component in the present compositions is beneficial in that reduced amounts of the composition may be required to be placed or injected into the posterior segment of the eye in order to provide the same amount or more corticosteroid component in the posterior segment of the eye relative to compositions, such as Kenalog®-40, which include less than 4% (w/v) of the corticosteroid component. Thus, in one very useful embodiment, the present compositions include more than about 4% (w/v), for example at least about 5% (w/v), to about 10% (w/v) or about 20% (w/v) or about 30% (w/v) of the corticosteroid component.
  • [0034]
    The viscosity inducing component is present in an effective amount in increasing, advantageously substantially increasing, the viscosity of the composition. Without wishing to limit the invention to any particular theory of operation, it is believed that increasing the viscosity of the compositions to values well in excess of the viscosity of water, for example, at least about 100 cps at a shear rate of 0.1/second, compositions which are highly effective for placement, e.g., injection, into the posterior segment of an eye of a human or animal are obtained. Along with the advantageous placement or injectability of the present compositions into the posterior segment, the relatively high viscosity of the present compositions are believed to enhance the ability of the present compositions to maintain the corticosteroid component particles in substantially uniform suspension in the compositions for prolonged periods of time, for example, for at least about one week, without requiring resuspension processing. The relatively high viscosity of the present compositions may also have an additional benefit of at least assisting the compositions to have the ability to have an increased amount or concentration of the corticosteroid component, as discussed elsewhere herein, for example, while maintaining such corticosteroid component in substantially uniform suspension for prolonged periods of time.
  • [0035]
    Advantageously, the present compositions have viscosities of at least about 10 cps or at least about 100 cps or at least about 1000 cps, more preferably at least about 10,000 cps and still more preferably at least about 70,000 cps or more, for example up to about 200,000 cps or about 250,000 cps, or about 300,000 cps or more, at a shear rate of 0.1/second. The present compositions not only have the relatively high viscosity as noted above but also have the ability or are structured or made up so as to be effectively placeable, e.g., injectable, into a posterior segment of an eye of a human or animal, preferably through a 27 gauge needle, or even through a 30 gauge needle.
  • [0036]
    The presently useful viscosity inducing components preferably are shear thinning components in that as the present composition containing such a shear thinning viscosity inducing component is passed or injected into the posterior segment of an eye, for example, through a narrow space, such as 27 gauge needle, under high shear conditions the viscosity of the composition is substantially reduced during such passage. After such passage, the composition regains substantially its pre-injection viscosity so as to maintain the corticosteroid component particles in suspension in the eye.
  • [0037]
    Any suitable viscosity inducing component, for example, ophthalmically acceptable viscosity inducing component, may be employed in accordance with the present invention. Many such viscosity inducing components have been proposed and/or used in ophthalmic compositions used on or in the eye. The viscosity inducing component is present in an amount effective in providing the desired viscosity to the composition. Advantageously, the viscosity inducing component is present in an amount in a range of about 0.5% or about 1.0% to about 5% or about 10% or about 20% (w/v) of the composition. The specific amount of the viscosity inducing component employed depends upon a number of factors including, for example and without limitation, the specific viscosity inducing component being employed, the molecular weight of the viscosity inducing component being employed, the viscosity desired for the present composition being produced and/or used and the like factors. The viscosity inducing component is chosen to provide at least one advantage, and preferably multiple advantages, to the present compositions, for example, in terms of each of injectability into the posterior segment of the eye, viscosity, sustainability of the corticosteroid component particles in suspension, for example, in substantially uniform suspension, for a prolonged period of time without resuspension processing, compatibility with the tissues in the posterior segment of the eye into which the composition is to be placed and the like advantages. More preferably, the selected viscosity inducing component is effective to provide two or more of the above-noted benefits, and still more preferably to provide all of the above-noted benefits.
  • [0038]
    The viscosity inducing component preferably comprises a polymeric component and/or at least one viscoelastic agent, such as those materials which are useful in ophthalmic surgical procedures.
  • [0039]
    Examples of useful viscosity inducing components include, but are not limited to, hyaluronic acid, carbomers, polyacrylic acid, cellulosic derivatives, polycarbophil, polyvinylpyrrolidone, gelatin, dextrin, polysaccharides, polyacrylamide, polyvinyl alcohol, polyvinyl acetate, derivatives thereof and mixtures thereof.
  • [0040]
    The molecular weight of the presently useful viscosity inducing components may be in a range of about 10,000 Daltons or less to about 2 million Daltons or more. In one particularly useful embodiment, the molecular weight of the viscosity inducing component is in a range of about 100,000 Daltons or about 200,000 Daltons to about 1 million Daltons or about 1.5 million Daltons. Again, the molecular weight of the viscosity inducing component useful in accordance with the present invention, may vary over a substantial range based on the type of viscosity inducing component employed, and the desired final viscosity of the present composition in question, as well as, possibly one or more other factors.
  • [0041]
    In one very useful embodiment, a viscosity inducing component is a polymeric hyaluronate component, for example, a metal hyaluronate component, preferably selected from alkali metal hyaluronates, alkaline earth metal hyaluronates and mixtures thereof, and still more preferably selected from sodium hyaluronates, and mixtures thereof. The molecular weight of such hyaluronate component preferably is in a range of about 50,000 Daltons or about 100,000 Daltons to about 1.3 million Daltons or about 2 million Daltons. In one embodiment, the present compositions include a polymeric hyaluronate component in an amount in a range about 0.05% to about 0.5% (w/v). In a further useful embodiment, the hyaluronate component is present in an amount in a range of about 1% to about 4% (w/v) of the composition. In this latter case, the very high polymer viscosity forms a gel that slows particle sedimentation rate to the extent that often no resuspension processing is necessary over the estimated shelf life, for example, at least about 2 years, of the composition. Such a composition may be marketed in pre-filled syringes since the gel cannot be easily removed by a needle and syringe from a bulk container.
  • [0042]
    The aqueous carrier component is advantageously ophthalmically acceptable and may include one or more conventional excipients useful in ophthalmic compositions.
  • [0043]
    The present compositions preferably include a major amount of liquid water. The present compositions may be, and are preferably, sterile, for example, prior to being used in the eye.
  • [0044]
    The present compositions preferably include at least one buffer component in an amount effective to control the pH of the composition and/or at least one tonicity component in an amount effective to control the tonicity or osmolality of the compositions. More preferably, the present compositions include both a buffer component and a tonicity component.
  • [0045]
    The buffer component and tonicity component may be chosen from those which are conventional and well known in the ophthalmic art.
  • [0046]
    Examples of such buffer components include, but are not limited to, acetate buffers, citrate buffers, phosphate buffers, borate buffers and the like and mixtures thereof. Phosphate buffers are particularly useful. Useful tonicity components include, but are not limited to, salts, particularly sodium chloride, potassium chloride, any other suitable ophthalmically acceptably tonicity component and mixtures thereof.
  • [0047]
    The amount of buffer component employed preferably is sufficient to maintain the pH of the composition in a range of about 6 to about 8, more preferably about 7 to about 7.5. The amount of tonicity component employed preferably is sufficient to provide an osmolality to the present compositions in a range of about 200 to about 400, more preferably about 250 to about 350, mOsmol/kg respectively. Advantageously, the present compositions are substantially isotonic.
  • [0048]
    The present compositions may include one or more other components in amounts effective to provide one or more useful properties and/or benefits to the present compositions. For example, although the present compositions may be substantially free of added preservative components, in other embodiments, the present compositions include effective amounts of preservative components, preferably such components which are more compatible with or friendly to the tissue in the posterior segment of the eye into which the composition is placed than benzyl alcohol. Examples of such preservative components include, without limitation, benzalkonium chloride, chlorhexidine, PHMB (polyhexamethylene biguanide), methyl and ethyl parabens, hexetidine, chlorite components, such as stabilized chlorine dioxide, metal chlorites and the like, other ophthalmically acceptable preservatives and the like and mixtures thereof. The concentration of the preservative component, if any, in the present compositions is a concentration effective to preserve the composition, and is often in a range of about 0.00001% to about 0.05% or about 0.1% (w/v) of the composition.
  • [0049]
    In addition, the present composition may include an effective amount of resuspension component effective to facilitate the suspension or resuspension of the corticosteroid component particles in the present compositions. As noted above, in certain embodiments, the present compositions are free of added resuspension components. In other embodiments of the present compositions effective amounts of resuspension components are employed, for example, to provide an added degree of insurance that the corticosteroid component particles remain in suspension, as desired and/or can be relatively easily resuspended in the present compositions, such resuspension be desired. Advantageously, the resuspension component employed in accordance with the present invention, if any, is chosen to be more compatible with or friendly to the tissue in the posterior segment of the eye into which the composition is placed than polysorbate 80.
  • [0050]
    Any suitable resuspension component may be employed in accordance with the present invention. Examples of such resuspension components include, without limitation, surfactants such as poloxanes, for example, sold under the trademark Pluronic®; tyloxapol; sarcosinates; polyethoxylated castor oils, other surfactants and the like and mixtures thereof.
  • [0051]
    One very useful class of resuspension components are those selected from vitamin derivatives. Although such materials have been previously suggested for use as surfactants in ophthalmic compositions, they have been found to be effective in the present compositions as resuspension components. Examples of useful vitamin derivatives include, without limitation, Vitamin E tocopheryl polyethylene glycol succinates, such as Vitamin E tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS). Other useful vitamin derivatives include, again without limitation, Vitamin E tocopheryl polyethylene glycol succinamides, such as Vitamin E tocopheryl polyethylene glycol 1000 succinamide (Vitamin E TPGSA) wherein the ester bond between polyethylene glycol and succinic acid is replaced by an amide group.
  • [0052]
    The presently useful resuspension components are present, if at all, in the compositions in accordance with the present invention in an amount effective to facilitate suspending the particles in the present compositions, for example, during manufacture of the compositions or thereafter. The specific amount of resuspension component employed may vary over a wide range depending, for example, on the specific resuspension component being employed, the specific composition in which the resuspension component is being employed and the like factors. Suitable concentrations of the resuspension component, if any, in the present compositions are often in a range of about 0.01% to about 5%, for example, about 0.02% or about 0.05% to about 1.0% (w/v) of the composition.
  • [0053]
    The availability of minimally soluble corticosteroid components, such as triamcinolone acetonide, to intraocular tissues may be limited by the dissolution rate for these substances. Slow dissolution is both good and bad for the patient. On the one hand, after a single intravitreal injection of the present composition, the mean elimination half-life for triamcinolone acetonide is advantageously quite long, for example, about 19 days in nonvitrectonized patients and measurable drug levels are detected for up to about 3 months. On the other hand, therapeutic drug levels in the vitreous compartment of the eye may not be achieved for about 1 to about 3 days, due to the slow dissolution rate of the corticosteroid component particles.
  • [0054]
    In one embodiment of the present invention, an effective amount of a solubilizing component is provided in the composition to solubilize a minor amount, that is less than 50%, for example in a range of 1% or about 5% to about 10% or about 20% of the corticosteroid component. For example, the inclusion of a cyclodextrin component, such as β-cyclodextrin, sulfo-butylether β-cyclodextrin (SBE), other cyclodextrins and the like and mixtures thereof, at about 0.5 to about 5.0% (w/v) solubilizes about 1 to about 10% of the initial dose of triamcinolone acetonide. This presolubilized fraction provides a readily bioavailable loading dose, thereby avoiding any delay time in therapeutic effectiveness.
  • [0055]
    The use of such a solubilizing component is advantageous to provide any relatively quick release of the corticosteroid component into the eye for therapeutic effectiveness. Such solubilizing component, of course, should be ophthalmically acceptable or at least sufficiently compatible with the posterior segment of the eye into which the composition is placed to avoid undue damage to the tissue in such posterior segment.
  • [0056]
    The pharmacokinetics of the corticosteroid component, for example, triamcinolone acetonide, following intravitreal administration may involve both the rate of drug dissolution and the rate of drug efflux via the anterior route. For example, following a single intravitreal injection of a composition containing 4% (w/v) of triamcinolone acetonide, TA concentration peaks (monitored in aqueous humor) after several days at thousands of nanograms per mL. This peak (Cmax) is followed by a rapid decrease lasting about 200 hours, and ends in a slow elimination phase with a half-life of about 19 days. Patients typically require repeat dosing, for example about every three months.
  • [0057]
    In one embodiment of the present invention, the compositions further contain sustained release components, for example, polymers, such as poly (D,L,-lactide) or poly(D,L-lactide co-glycolide), in amounts effective to reduce local diffusion rates and/or corticosteroid particle dissolution rates. The result is a flatter elimination rate profile with a lower Cmax and a more prolonged therapeutic window, thereby extending the time between required injections for many patients.
  • [0058]
    Any suitable, preferably conditionally acceptable, release component may be employed. Useful examples are set forth above. The sustained release component is preferably biodegradable or bioabsorbable in the eye so that no residue remains over the long term. The amount of the delayed release component included may very over a relatively wide range depending, for example, on the specific sustained release component is being employed, the specific release profile desired and the like factors. Typical amounts of delayed release components, if any, included in the present compositions are in a range of about 0.05 to 0.1 to about 0.5 or about 1 or more percent (w/v) of the composition.
  • [0059]
    The present compositions can be prepared using suitable blending/processing techniques or techniques, for example, one or more conventional blending techniques. The preparation processing should be chosen to provide the present compositions in forms which are useful for placement or injection into the posterior segments of eyes of humans or animals. In one useful embodiment a concentration corticosteroid component dispersion is made by combining the corticosteroid component with water, and the excipient (other than the viscosity inducing component) to be included in the final composition. The ingredients are mixed to disperse the corticosteroid component and then autoclaved. Alternatively, the steroid powder may be γ-irradiated before addition to the sterile carrier. The viscosity inducing component may be purchased sterile or sterilized by conventional processing, for example, by filtering a dilute solution followed by lyophylization to yield a sterile powder. The sterile viscosity inducing component is combined with water to make an aqueous concentrate. Under aseptic conditions, the concentrated corticosteroid component dispersion is mixed and added as a slurry to the viscosity inducing component concentrate. Water is added in a quantity sufficient (q.s.) to provide the desired composition and the composition is mixed until homogenous.
  • [0060]
    Methods of using the present composition are provided and are included within the scope of the present invention. In general, such methods comprise administering a composition in accordance with the present invention to a posterior segment of an eye of a human or animal, thereby obtaining a desired therapeutic effect. The administering step advantageously comprises at least one of intravitreal injecting, subconjunctival injecting, sub-tenon injecting, retrobulbar injecting, suprachoroidal injecting and the like. A syringe apparatus including an appropriately sized needle, for example, a 27 gauge needle or a 30 gauge needle, can be effectively used to inject the composition with the posterior segment of an eye of a human or animal.
  • [0061]
    Among the diseases/conditions which can be treated or addressed in accordance with the present invention include, without limitation, the following:
  • [0062]
    MACULOPATHIES/RETINAL DEGENERATION: Non-Exudative Age Related Macular Degeneration (ARMD), Exudative Age Related Macular Degeneration (ARMD), Choroidal Neovascularization, Diabetic Retinopathy, Acute Macular Neuroretinopathy, Central Serous Chorioretinopathy, Cystoid Macular Edema, Diabetic Macular Edema.
  • [0063]
    UVEITIS/RETINITIS/CHOROIDITIS: Acute Multifocal Placoid Pigment Epitheliopathy, Behcet's Disease, Birdshot Retinochoroidopathy, Infectious (Syphilis, Lyme, Tuberculosis, Toxoplasmosis), Intermediate Uveitis (Pars Planitis), Multifocal Choroiditis, Multiple Evanescent White Dot Syndrome (MEWDS), Ocular Sarcoidosis, Posterior Scleritis, Serpignous Choroiditis, Subretinal Fibrosis and Uveitis Syndrome, Vogt-Koyanagi-Harada Syndrome.
  • [0064]
    VASCULAR DISEASES/EXUDATIVE DISEASES: Retinal Arterial Occlusive Disease, Central Retinal Vein Occlusion, Disseminated Intravascular Coagulopathy, Branch Retinal Vein Occlusion, Hypertensive Fundus Changes, Ocular Ischemic Syndrome, Retinal Arterial Microaneurysms, Coat's Disease, Parafoveal Telangiectasis, Hemi-Retinal Vein Occlusion, Papillophlebitis, Central Retinal Artery Occlusion, Branch Retinal Artery Occlusion, Carotid Artery Disease (CAD), Frosted Branch Angitis, Sickle Cell Retinopathy and other Hemoglobinopathies, Angioid Streaks, Familial Exudative Vitreoretinopathy, Eales Disease.
  • [0065]
    TRAUMATIC/SURGICAL: Sympathetic Ophthalmia, Uveitic Retinal Disease, Retinal Detachment, Trauma, Laser, PDT, Photocoagulation, Hypoperfusion During Surgery, Radiation Retinopathy, Bone Marrow Transplant Retinopathy.
  • [0066]
    PROLIFERATIVE DISORDERS: Proliferative Vitreal Retinopathy and Epiretinal Membranes, Proliferative Diabetic Retinopathy.
  • [0067]
    INFECTIOUS DISORDERS: Ocular Histoplasmosis, Ocular Toxocariasis, Presumed Ocular Histoplasmosis Syndrome (POHS), Endophthalmitis, Toxoplasmosis, Retinal Diseases Associated with HIV Infection, Choroidal Disease Associated with HIV Infection, Uveitic Disease Associated with HIV Infection, Viral Retinitis, Acute Retinal Necrosis, Progressive Outer Retinal Necrosis, Fungal Retinal Diseases, Ocular Syphilis, Ocular Tuberculosis, Diffuse Unilateral Subacute Neuroretinitis, Myiasis.
  • [0068]
    GENETIC DISORDERS: Retinitis Pigmentosa, Systemic Disorders with Accosiated Retinal Dystrophies, Congenital Stationary Night Blindness, Cone Dystrophies, Stargardt's Disease and Fundus Flavimaculatus, Best's Disease, Pattern Dystrophy of the Retinal Pigmented Epithelium, X-Linked Retinoschisis, Sorsby's Fundus Dystrophy, Benign Concentric Maculopathy, Bietti's Crystalline Dystrophy, pseudoxanthoma elasticum.
  • [0069]
    RETINAL TEARS/HOLES: Retinal Detachment, Macular Hole, Giant Retinal Tear.
  • [0070]
    TUMORS: Retinal Disease Associated with Tumors, Congenital Hypertrophy of the RPE, Posterior Uveal Melanoma, Choroidal Hemangioma, Choroidal Osteoma, Choroidal Metastasis, Combined Hamartoma of the Retina and Retinal Pigmented Epithelium, Retinoblastoma, Vasoproliferative Tumors of the Ocular Fundus, Retinal Astrocytoma, Intraocular Lymphoid Tumors.
  • [0071]
    MISCELLANEOUS: Punctate Inner Choroidopathy, Acute Posterior Multifocal Placoid Pigment Epitheliopathy, Myopic Retinal Degeneration, Acute Retinal Pigement Epithelitis and the like.
  • [0072]
    The present methods may comprise a single injection into the posterior segment of an eye or may involve repeated injections, for example over periods of time ranging from about one week or about 1 month or about 3 months to about 6 months or about 1 year or longer.
  • [0073]
    The following non-limiting Examples illustrate certain aspects of the present invention.
  • EXAMPLES 1 TO 4
  • [0074]
    Four compositions are as follows:
    Ingredient Example 1 Example 2 Example 3 Example 4
    Triacinolone acetonide   2%   2%   4%   4% (w/v)
    (w/v) (w/v) (w/v)
    Sodium Hyaluronate 0.05% 0.5% 0.05% 0.5%
    (0.6 × 106 DALTONS) (w/v) (w/v) (w/v) (w/v)
    Sodium Phosphate  0.4% 0.4%  0.4% 0.4%
    (w/v) (w/v) (w/v) (w/v)
    Vitamin E-TPGS  0.5% 0.5%  0.0 0.0
    (w/v) (w/v)
    λ-cyclodextrin  0.5% 0.5%  0.0 0.0
    (w/v) (w/v)
    Water for Injection q.s. q.s. q.s. q.s.
    Viscosity at shear rate 20 cps 500 cps 20 cps 500 cps
    0.1/second
  • [0075]
    Each of these compositions is prepared as follows.
  • [0076]
    A concentrated triamcinolone acetonide dispersion is made by combining triamcinolone acetonide with water, Vitamin E-TPGS and λ-cyclodextrin, if any. These ingredients are mixed to disperse the triamcinolone acetonide, and then autoclaved. The sodium hyaluronate may be purchased as a sterile powder or sterilized by filtering a dilute solution followed by lyophylization to yield a sterile powder. The sterile sodium hyaluronate is dissolved in water to make an aqueous concentrate. The concentrated triamcinolone acetonide dispersion is mixed and added as a slurry to the sodium hyaluronate concentrate. Water is added q.s. and the mixture is mixed until homogenous.
  • [0077]
    Each of these compositions produced a loose floctuation of triamcinolone acetonide that is easily re-suspended by gentle inversion. These compositions can be marketed in small volume pharmaceutical grade glass bottles, and are found to be therapeutically effective against macular edema when injected intravitreally into human eyes.
  • EXAMPLES 5 TO 7
  • [0078]
    Three compositions are as follows:
    Ingredient Example 5 Example 6 Example 7
    Triamcinolone 2.0% (w/v) 4.0% (w/v) 8.0% (w/v)
    acetonide
    Sodium hyaluronate 3.0% (w/v) 2.5% (w/v) 2.0% (w/v)
    Sodium Phosphate 0.4% (w/v) 0.4% (w/v) 0.4% (w/v)
    Water for Injection q.s. q.s. q.s.
    Viscosity at shear 180,000 cps 120,000 cps 80,000 cps
    rate 0.1/second
  • [0079]
    These compositions are prepared in a manner substantially analogous to that set forth in Example 1.
  • [0080]
    The high viscosities of the compositions substantially slows the particle sedimentation rate to an extent that no resuspension processing is necessary or required over the estimated shelf life, e.g., about 2 years, of the compositions. These compositions can be marketed in prefilled syringes since they can not easily be removed by a needle and syringe from a container. However, with the compositions in prefilled syringes, the compositions can be effectively injected into the posterior segment of an eye of a human using a 27 gauge or a 30 gauge needle to provide a desired therapeutic effect in the human eye.
  • [0081]
    The compositions of Examples 5 to 7 employ or contain a sufficient concentration of high molecular weight sodium hyaluronate so as to form a gelatinous plug or drug depot upon intravitreal injection into a human eye. Triamcinolone acetonide particles are, in effect, trapped or held within this viscous plug, so that undesirable “pluming” does not occur, and the risk of drug particles disadvantageously settling directly on the retinal tissue is substantially reduced, for example, relative to using a composition with a water like viscosity, such as Kenalog® 40. Since sodium hyaluronate solutions are subject to dramatic shear thinning, these formulations are easily injected through 27 gauge or even 30 gauge needles.
  • EXAMPLES 8 AND 9
  • [0082]
    Two compositions are as follows:
    Ingredient Example 8 Example 9
    Triamcinolone acetonide  2.0% (w/v)  8.0% (w/v)
    Sodium hyaluronate  2.5% (w/v)  2.3% (w/v)
    Sodium chloride 0.63% (w/v)  0.6% (w/v)
    dibasic sodium phosphate, 0.30% (w/v) 0.30% (w/v)
    heptahydrate
    Monobasic sodium phosphate, 0.04% (w/v) 0.04% (w/v)
    monohydrate
    Water for Injection q.s. q.s.
    Viscosity at shear rate 170,000 ± 25% cps 200,000 ± 25% cps
    0.1/second
  • [0083]
    These compositions are prepared in a manner substantially analogous to that set forth in Example 1.
  • [0084]
    The high viscosities of the compositions substantially slows the particle sedimentation rate to an extent that no resuspension processing is necessary or required over the estimated shelf life, e.g., about 2 years, of the compositions. These compositions can be marketed in prefilled syringes since they can not easily be removed by a needle and syringe from a container. However, with the compositions in prefilled syringes, the compositions can be effectively injected into the posterior segment of an eye of a human using a 27 gauge or a 30 gauge needle to provide a desired therapeutic effect in the human eye.
  • [0085]
    The sodium hyaluronate powders used in these compositions (as well as in the other compositions identified in the Examples herein) have water contents in a range of about 4% to about 20%, preferably about 4% to about 8%, by weight. The water content of the powder, and in particular the variation in water contents for powder to powder, can result in variations in the viscosities of two or more compositions in accordance with the present invention which have the same “nominal” chemical make-ups. Thus, the viscosities indicated herein should be understood to be target viscosities, with the composition being acceptable for use if the actual viscosity of the composition is within plus or minus (±) about 25% or about 30% or about 35% of the target viscosity.
  • [0086]
    Because each of the compositions set forth in the Examples has a density of about 1 gm/ml, the percentages set forth herein as being based on weight per volume (w/v) can also be considered as being based on weight per weight (w/w).
  • [0087]
    The compositions of Examples 8 and 9 employ or contain a sufficient concentration of high molecular weight sodium hyaluronate so as to form a gelatinous plug or drug depot upon intravitreal injection into a human eye. Triamcinolone acetonide particles are, in effect, trapped or held within this viscous plug, so that undesirable “pluming” does not occur, and the risk of drug particles disadvantageously settling directly on the retinal tissue is substantially reduced, for example, relative to using a composition with a water like viscosity, such as Kenalog® 40. Since sodium hyaluronate solutions are subject to dramatic shear thinning, these formulations are easily injected through 27 gauge or even 30 gauge needles.
  • [0088]
    While this invention has been described with respect to various specific examples and embodiments, it is to be understood that the invention is not limited thereto and that it can be variously practiced within the scope of the following claims.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3396081 *Mar 16, 1966Aug 6, 1968Etapharm Chem Pharm Lab Ges MHyaluronic acid preparation and method of producing same
US4008864 *Feb 18, 1975Feb 22, 1977Nils Gustav Yngve TorphammarLocking mechanism for a safety belt
US4014335 *Mar 25, 1976Mar 29, 1977Alza CorporationOcular drug delivery device
US4088864 *Feb 23, 1976May 9, 1978Alza CorporationProcess for forming outlet passageways in pills using a laser
US4144317 *Sep 21, 1977Mar 13, 1979Alza CorporationDevice consisting of copolymer having acetoxy groups for delivering drugs
US4158005 *May 9, 1977Jun 12, 1979Interx Research CorporationIntermediates useful in the synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols
US4186184 *Apr 23, 1979Jan 29, 1980Alza CorporationSelective administration of drug with ocular therapeutic system
US4190642 *May 11, 1979Feb 26, 1980Alza CorporationOcular therapeutic system for dispensing a medication formulation
US4200098 *Oct 23, 1978Apr 29, 1980Alza CorporationOsmotic system with distribution zone for dispensing beneficial agent
US4327725 *Nov 25, 1980May 4, 1982Alza CorporationOsmotic device with hydrogel driving member
US4383992 *Feb 8, 1982May 17, 1983Lipari John MWater-soluble steroid compounds
US4425346 *Jan 25, 1982Jan 10, 1984Smith And Nephew Associated Companies LimitedPharmaceutical compositions
US4494274 *Dec 8, 1982Jan 22, 1985Thurlow Heida LCookware with covers having metal handles
US4521210 *Dec 27, 1982Jun 4, 1985Wong Vernon GEye implant for relieving glaucoma, and device and method for use therewith
US4599353 *May 3, 1982Jul 8, 1986The Trustees Of Columbia University In The City Of New YorkUse of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4649151 *May 14, 1984Mar 10, 1987Health Research, Inc.Drugs comprising porphyrins
US4656186 *Apr 30, 1985Apr 7, 1987Nippon Petrochemicals Co., Ltd.Tetrapyrrole therapeutic agents
US4668506 *Aug 16, 1985May 26, 1987Bausch & Lomb IncorporatedSustained-release formulation containing and amino acid polymer
US4675338 *Jul 18, 1984Jun 23, 1987Nippon Petrochemicals Co., Ltd.Tetrapyrrole therapeutic agents
US4727064 *May 29, 1985Feb 23, 1988The United States Of America As Represented By The Department Of Health And Human ServicesPharmaceutical preparations containing cyclodextrin derivatives
US4920104 *May 16, 1988Apr 24, 1990Medchem Products, Inc.Sodium hyaluronate composition
US4932934 *Aug 24, 1988Jun 12, 1990Health Research, Inc.Methods for treatment of tumors
US4935498 *Mar 6, 1989Jun 19, 1990Board Of Regents, The University Of Texas SystemExpanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US4981871 *May 15, 1987Jan 1, 1991Abelson Mark BTreatment of ocular hypertension with class I calcium channel blocking agents
US5002962 *Jul 20, 1988Mar 26, 1991Health Research, Inc.Photosensitizing agents
US5017579 *Feb 6, 1989May 21, 1991SanofiUse of aminoalkoxyphenyl derivatives for reducing and/or controlling excessive intraocular pressure
US5019400 *May 1, 1989May 28, 1991Enzytech, Inc.Very low temperature casting of controlled release microspheres
US5025621 *Mar 16, 1990Jun 25, 1991Demarco Vito ACombination garden implement
US5034413 *Sep 18, 1990Jul 23, 1991Allergan, Inc.Intraocular pressure reducing 9,11-diacyl prostaglandins
US5089509 *Mar 20, 1989Feb 18, 1992Allergan, Inc.Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5093349 *Oct 15, 1990Mar 3, 1992Health Research Inc.Photosensitizing agents
US5100431 *Sep 27, 1990Mar 31, 1992Allergan, Inc.Single stitch suture needle and method
US5106615 *Nov 30, 1990Apr 21, 1992Shabtay DiksteinEyedrops having non-newtonian rheological properties
US5190966 *Sep 18, 1990Mar 2, 1993Health Research, Inc.Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US5198460 *Jan 17, 1992Mar 30, 1993Health Research Inc.Pyropheophorbides and their use in photodynamic therapy
US5209926 *Aug 24, 1992May 11, 1993Insite Vision IncorporatedAminosteroids for ophthalmic use
US5300114 *Aug 10, 1992Apr 5, 1994Allergan, Inc.Subconjunctival implants for ocular drug delivery
US5314905 *Nov 9, 1992May 24, 1994Health Research, Inc.Pyropheophorbides conjugates and their use in photodynamic therapy
US5324519 *Oct 28, 1991Jun 28, 1994Atrix Laboratories, Inc.Biodegradable polymer composition
US5324718 *Jul 14, 1992Jun 28, 1994Thorsteinn LoftssonCyclodextrin/drug complexation
US5332582 *Dec 2, 1992Jul 26, 1994Insite Vision IncorporatedStabilization of aminosteroids for topical ophthalmic and other applications
US5385887 *Sep 10, 1993Jan 31, 1995Genetics Institute, Inc.Formulations for delivery of osteogenic proteins
US5487897 *Sep 28, 1993Jan 30, 1996Atrix Laboratories, Inc.Biodegradable implant precursor
US5494901 *Jan 5, 1993Feb 27, 1996Javitt; Jonathan C.Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
US5501856 *Nov 27, 1991Mar 26, 1996Senju Pharmaceutical Co., Ltd.Controlled-release pharmaceutical preparation for intra-ocular implant
US5504074 *Aug 6, 1993Apr 2, 1996Children's Medical Center CorporationEstrogenic compounds as anti-angiogenic agents
US5516522 *Mar 14, 1994May 14, 1996Board Of Supervisors Of Louisiana State UniversityBiodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5597897 *Jun 22, 1992Jan 28, 1997Genetics Institute, Inc.Pharmaceutical formulations of osteogenic proteins
US5707643 *Jun 7, 1996Jan 13, 1998Santen Pharmaceutical Co., Ltd.Biodegradable scleral plug
US5717030 *Dec 6, 1996Feb 10, 1998Atrix Laboratories, Inc.Adjunctive polymer system for use with medical device
US5747061 *Jul 29, 1996May 5, 1998Pharmos CorporationSuspension of loteprednol etabonate for ear, eye, or nose treatment
US5766242 *Mar 13, 1996Jun 16, 1998Oculex Pharmaceuticals, Inc.Biocompatible ocular implants
US5770589 *Jul 27, 1994Jun 23, 1998The University Of SydneyTreatment of macular degeneration
US5776699 *Mar 11, 1996Jul 7, 1998Allergan, Inc.Method of identifying negative hormone and/or antagonist activities
US5780044 *Dec 5, 1996Jul 14, 1998Atrix Laboratories, Inc.Liquid delivery compositions
US5869079 *Jun 2, 1995Feb 9, 1999Oculex Pharmaceuticals, Inc.Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5877207 *Jun 24, 1997Mar 2, 1999Allergan Sales, Inc.Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5882682 *Oct 19, 1995Mar 16, 1999Merck & Co., Inc.Controlled release simvastatin delivery device
US5906920 *Aug 29, 1995May 25, 1999The Salk Institute For Biological StudiesMethods for the detection of ligands for retinoid X receptors
US5913884 *Oct 31, 1996Jun 22, 1999The General Hospital CorporationInhibition of fibrosis by photodynamic therapy
US5919970 *Apr 24, 1997Jul 6, 1999Allergan Sales, Inc.Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US5922773 *Dec 4, 1992Jul 13, 1999The Children's Medical Center Corp.Glaucoma treatment
US6051576 *Jan 29, 1997Apr 18, 2000University Of Kentucky Research FoundationMeans to achieve sustained release of synergistic drugs by conjugation
US6066675 *Sep 8, 1997May 23, 2000The Regents Of The University Of CaliforniaMethod for treatment of retinal diseases
US6074661 *Sep 10, 1998Jun 13, 2000Allergan Sales, Inc.Sterile bioerodible occular implant device with a retinoid for improved biocompatability
US6217869 *Sep 5, 1997Apr 17, 2001Neorx CorporationPretargeting methods and compounds
US6225303 *Jul 6, 1999May 1, 2001Massachusetts Eye And Ear InfirmaryUse of green porphyrins to treat neovasculature in the eye
US6242480 *Dec 16, 1997Jun 5, 2001Alcon Laboratories, Inc.Ophthalmic viscoelastic compositions
US6257568 *May 26, 2000Jul 10, 2001Vijuk Equipment, Inc.Accumulator station with stack height control
US6258319 *Sep 4, 1998Jul 10, 2001Cerus CorporationDevice and method for photoactivation
US6261583 *Jul 28, 1998Jul 17, 2001Atrix Laboratories, Inc.Moldable solid delivery system
US6369116 *Dec 23, 1998Apr 9, 2002Oculex Pharmaceuticals, Inc.Composition and method for treating glaucoma
US6387409 *Jan 4, 2000May 14, 2002Rtp Pharma Inc.Composition and method of preparing microparticles of water-insoluble substances
US6395293 *Mar 8, 2000May 28, 2002Atrix LaboratoriesBiodegradable implant precursor
US6395294 *Jan 13, 2000May 28, 2002Gholam A. PeymanMethod of visualization of the vitreous during vitrectomy
US6403649 *Mar 6, 2000Jun 11, 2002Allergan Sales, Inc.Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US6407079 *Oct 31, 1988Jun 18, 2002Janssen Pharmaceutica N.V.Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US6537568 *Oct 17, 2001Mar 25, 2003Allergan, Inc.Implant device with a retinoid for improved biocompatibility
US6565871 *Aug 31, 2001May 20, 2003Elan Drug Delivery Ltd.Solid dose delivery vehicle and methods of making same
US6565874 *Nov 13, 2000May 20, 2003Atrix LaboratoriesPolymeric delivery formulations of leuprolide with improved efficacy
US6573280 *Jan 2, 2002Jun 3, 2003Allergan, Inc.Calcium blockers to treat proliferative vitreoretinopathy
US6595945 *Jan 9, 2001Jul 22, 2003J. David BrownGlaucoma treatment device and method
US6699493 *Nov 28, 2001Mar 2, 2004Oculex Pharmaceuticals, Inc.Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6713081 *Mar 15, 2001Mar 30, 2004The United States Of America As Represented By The Department Of Health And Human ServicesOcular therapeutic agent delivery devices and methods for making and using such devices
US6713268 *Jun 26, 2001Mar 30, 2004Allergan, Inc.Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
US6723353 *Nov 20, 2001Apr 20, 2004Allergan, Inc.Preserved cyclodextrin-containing compositions
US6726918 *Oct 20, 2000Apr 27, 2004Oculex Pharmaceuticals, Inc.Methods for treating inflammation-mediated conditions of the eye
US6765012 *Sep 27, 2002Jul 20, 2004Allergan, Inc.3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US6899717 *Sep 18, 2002May 31, 2005Allergan, Inc.Methods and apparatus for delivery of ocular implants
US20020094998 *Nov 1, 2001Jul 18, 2002Burke James A.Methods and compositions for treatment of ocular neovascularization and neural injury
US20030060763 *Jan 8, 2001Mar 27, 2003Penfold Philip LeslieGuide means for intraocular injection
US20030069286 *May 22, 2002Apr 10, 2003Bardeen Sciences Co., LlcHypotensive lipid and timolol compositions and methods of using same
US20030095995 *Dec 20, 2002May 22, 2003Vernon WongFormulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20040054374 *Sep 18, 2002Mar 18, 2004David WeberMethods and apparatus for delivery of ocular implants
US20040077562 *Nov 12, 2001Apr 22, 2004Chandavarkar Mohan A.Combination drug
US20040137059 *Jan 9, 2003Jul 15, 2004Thierry NivaggioliBiodegradable ocular implant
US20060009498 *Jul 11, 2005Jan 12, 2006Allergan, Inc.Ophthalmic compositions and methods for treating ophthalmic conditions
US20060141049 *Feb 14, 2006Jun 29, 2006Allergan, Inc.Triamcinolone compositions for intravitreal administration to treat ocular conditions
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7767223Aug 3, 2010Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
US7846468Dec 7, 2010Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US8034366Oct 11, 2011Allergan, Inc.Ocular implant made by a double extrusion process
US8034370Oct 31, 2007Oct 11, 2011Allergan, Inc.Ocular implant made by a double extrusion process
US8043628Oct 31, 2007Oct 25, 2011Allergan, Inc.Methods for reducing edema
US8062657Oct 18, 2006Nov 22, 2011Allergan, Inc.Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
US8071120Dec 6, 2011Allergan, Inc.Methods for treating neovascularization and intravitreal implants
US8076485Oct 29, 2008Dec 13, 2011Institute For Molecular Medicine, Inc.Methylphenidate derivatives and uses of them
US8088407Sep 7, 2007Jan 3, 2012Allergan, Inc.Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US8128960Mar 10, 2009Mar 6, 2012Alcon Research, Ltd.Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
US8211880Jan 17, 2012Jul 3, 2012Alcon Research, Ltd.Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
US8217047May 27, 2009Jul 10, 2012Dmi Acquisition Corp.Therapeutic methods and compounds
US8242099Aug 14, 2012Allergan, Inc.Implants and methods for treating inflammation-mediated conditions of the eye
US8263110Sep 11, 2012Allergan, Inc.Sustained release intraocular implants and related methods
US8298570Oct 30, 2012Allergan, Inc.Sustained release intraocular implants and related methods
US8318070Nov 27, 2012Allergan, Inc.Ocular implant made by a double extrusion process
US8318695Nov 27, 2012Allergan, Inc.Tunably crosslinked polysaccharide compositions
US8338375Dec 25, 2012Allergan, Inc.Packaged product
US8338388May 18, 2010Dec 25, 2012Allergan, Inc.Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US8357795Feb 26, 2009Jan 22, 2013Allergan, Inc.Hyaluronic acid-based gels including lidocaine
US8394782Nov 21, 2008Mar 12, 2013Allergan, Inc.Polysaccharide gel formulation having increased longevity
US8394783Mar 12, 2013Allergan, Inc.Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394784Nov 10, 2009Mar 12, 2013Allergan, Inc.Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8440216May 14, 2013Allergan, Inc.Sustained release intraocular implants and related methods
US8450475Feb 26, 2009May 28, 2013Allergan, Inc.Hyaluronic acid-based gels including lidocaine
US8506987Aug 19, 2011Aug 13, 2013Allergan, Inc.Ocular implant made by a double extrusion process
US8513216Sep 11, 2009Aug 20, 2013Allergan, Inc.Polysaccharide gel formulation having increased longevity
US8563532Aug 3, 2012Oct 22, 2013Allergan Industrie SasCross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US8569272Jul 11, 2008Oct 29, 2013Allergan, Inc.Methods for treating a posterior segment of an eye
US8586562May 10, 2010Nov 19, 2013Allergan Industrie, SasFluid compositions for improving skin conditions
US8647659Jan 21, 2011Feb 11, 2014Allergan, Inc.Intracameral sustained release therapeutic agent implants
US8691279Mar 21, 2011Apr 8, 2014Allergan, Inc.Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8697044Oct 7, 2008Apr 15, 2014Allergan, Inc.Crossed-linked hyaluronic acid and collagen and uses thereof
US8697057Feb 16, 2012Apr 15, 2014Allergan, Inc.Compositions and soft tissue replacement methods
US8703118Mar 8, 2012Apr 22, 2014Allergan, Inc.Crossed-linked hyaluronic acid and collagen and uses thereof
US8771722Jan 24, 2012Jul 8, 2014Allergan, Inc.Methods of treating ocular disease using steroid-containing sustained release intraocular implants
US8771745Aug 28, 2012Jul 8, 2014Allergan, Inc.Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US8778381Mar 12, 2013Jul 15, 2014Allergan, Inc.Ocular implant made by a double extrusion process
US8802128Jul 21, 2006Aug 12, 2014Allergan, Inc.Steroid-containing sustained release intraocular implants and related methods
US8802129Jul 19, 2013Aug 12, 2014Allergan, Inc.Methods for treating retinopathy with extended therapeutic effect
US8822676Mar 13, 2012Sep 2, 2014Allergan Industrie, SasHyaluronic acid-based gels including lidocaine
US8828446Apr 26, 2013Sep 9, 2014Allergan, Inc.Method for reducing transplant rejection in the eye and intraocular implants for use therefor
US8846094Jul 26, 2007Sep 30, 2014Allergan, Inc.Peripherally administered viscous formulations
US8853184Mar 27, 2013Oct 7, 2014Allergan, Inc.Polysaccharide gel formulation having increased longevity
US8871772Feb 23, 2012Oct 28, 2014Ampio Pharmaceuticals, Inc.Therapeutic methods and compounds
US8883139Feb 16, 2012Nov 11, 2014Allergan Inc.Compositions and soft tissue replacement methods
US8889123Feb 16, 2012Nov 18, 2014Allergan, Inc.Compositions and soft tissue replacement methods
US8911768Jun 17, 2014Dec 16, 2014Allergan, Inc.Methods for treating retinopathy with extended therapeutic effect
US8921338Nov 12, 2013Dec 30, 2014Allergan Industrie, SasFluid compositions for improving skin conditions
US8946192May 24, 2012Feb 3, 2015Allergan, Inc.Heat stable hyaluronic acid compositions for dermatological use
US8962009Mar 15, 2013Feb 24, 2015Allergan, Inc.Sustained release intraocular implants and related methods
US9005605Feb 16, 2012Apr 14, 2015Allergan, Inc.Compositions and soft tissue replacement methods
US9012437May 3, 2013Apr 21, 2015Allergan, Inc.Implants and methods for treating inflammation-mediated conditions of the eye
US9012517Mar 19, 2014Apr 21, 2015Allergan, Inc.Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US9050336May 8, 2012Jun 9, 2015Allergan, Inc.Botulinum toxin formulation
US9062130Sep 12, 2013Jun 23, 2015Allergan Industrie SasCross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US9089478Aug 19, 2014Jul 28, 2015Allergen, Inc.Peripherally administered viscous formulations
US9089517Oct 16, 2012Jul 28, 2015Allergan Industrie SasHyaluronic acid-based gels including lidocaine
US9089518Oct 16, 2012Jul 28, 2015Allergan Industrie SasHyaluronic acid-based gels including lidocaine
US9089519Apr 1, 2014Jul 28, 2015Allergan Industrie SasHyaluronic acid-based gels including lidocaine
US9114188Jan 13, 2012Aug 25, 2015Allergan, Industrie, S.A.S.Stable hydrogel compositions including additives
US9125840Nov 12, 2013Sep 8, 2015Allergan Industrie SasMethods for improving skin conditions
US9149422Jun 1, 2012Oct 6, 2015Allergan, Inc.Dermal filler compositions including antioxidants
US9180047Oct 24, 2014Nov 10, 2015Clearside Biomedical, Inc.Apparatus and methods for ocular injection
US9192511Jun 20, 2013Nov 24, 2015Allergan, Inc.Ocular implant made by a double extrusion process
US9228027Sep 2, 2009Jan 5, 2016Allergan Holdings France S.A.S.Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9233071Nov 14, 2014Jan 12, 2016Allergan, Inc.Methods for treating retinopathy with extended therapeutic effect
US9233113Jun 22, 2010Jan 12, 2016Ampio Pharmaceuticals, Inc.Method for treatment of diseases
US9238013Jan 21, 2013Jan 19, 2016Allergan Industrie, SasHyaluronic acid-based gels including lidocaine
US9241829Dec 20, 2011Jan 26, 2016Abbott Medical Optics Inc.Implantable intraocular drug delivery apparatus, system and method
US9265761Feb 16, 2014Feb 23, 2016Allergan, Inc.Compositions and methods for treating purpura
US9265775Oct 28, 2013Feb 23, 2016Allergan, Inc.Pharmaceutical compositions
US9283178Sep 9, 2014Mar 15, 2016Allergan, Inc.Methods for treating edema in the eye and intraocular implants for use therefor
US9333160Nov 13, 2012May 10, 2016Allergan Industrie, SasHeat stable hyaluronic acid compositions for dermatological use
US9351979Dec 19, 2013May 31, 2016Ampio Pharmaceuticals, Inc.Methods of treatment of diseases
US9358322May 9, 2013Jun 7, 2016Allergan Industrie SasHyaluronic acid-based gels including lidocaine
US9393263Aug 23, 2012Jul 19, 2016Allergan, Inc.Dermal filler compositions including antioxidants
US9408797Sep 13, 2012Aug 9, 2016Allergan, Inc.Dermal filler compositions for fine line treatment
US20050048099 *Aug 13, 2004Mar 3, 2005Allergan, Inc.Ocular implant made by a double extrusion process
US20050191334 *Apr 29, 2005Sep 1, 2005Allergan, Inc.Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20050244469 *Apr 30, 2004Nov 3, 2005Allergan, Inc.Extended therapeutic effect ocular implant treatments
US20050250737 *Mar 28, 2005Nov 10, 2005Allergan, Inc.Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20060009498 *Jul 11, 2005Jan 12, 2006Allergan, Inc.Ophthalmic compositions and methods for treating ophthalmic conditions
US20060067966 *Nov 14, 2005Mar 30, 2006Allergan, Inc.Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060141049 *Feb 14, 2006Jun 29, 2006Allergan, Inc.Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20060183773 *Jan 20, 2006Aug 17, 2006David Bar-OrUses of methylphenidate derivatives
US20060204543 *May 12, 2006Sep 14, 2006Allergan, Inc.Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060233859 *Dec 2, 2005Oct 19, 2006Allergan, Inc.Methods for treating retinopathy with extended therapeutic effect
US20060280774 *May 23, 2006Dec 14, 2006Allergan, Inc.Compositions and methods for treating glaucoma
US20070088014 *Oct 18, 2006Apr 19, 2007Allergan, Inc.Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
US20070178138 *Feb 1, 2006Aug 2, 2007Allergan, Inc.Biodegradable non-opthalmic implants and related methods
US20070190112 *Apr 20, 2007Aug 16, 2007Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20070202186 *Feb 21, 2007Aug 30, 2007Iscience Interventional CorporationApparatus and formulations for suprachoroidal drug delivery
US20070224278 *Apr 27, 2007Sep 27, 2007Lyons Robert TLow immunogenicity corticosteroid compositions
US20070260203 *May 4, 2006Nov 8, 2007Allergan, Inc.Vasoactive agent intraocular implant
US20070275030 *May 25, 2007Nov 29, 2007The General Hospital Corporation Dba Massachusetts General HospitalAnti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
US20070298076 *Sep 7, 2007Dec 27, 2007Allergan, Inc.Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20080044476 *Jul 26, 2007Feb 21, 2008Allergan, Inc.Peripherally administered viscous formulations
US20080069859 *Nov 21, 2007Mar 20, 2008Allergan, Inc.Method for treating neovascularization and intravitreal implants
US20080107712 *Oct 31, 2007May 8, 2008Allergan, Inc.Ocular implant made by a double extrusion process
US20080131486 *Feb 14, 2008Jun 5, 2008Allergan, Inc.Sustained release intraocular implants and related methods
US20080268051 *Apr 30, 2007Oct 30, 2008Allergan, Inc.High viscosity macromolecular compositions for treating ocular conditions
US20080269181 *Jul 11, 2008Oct 30, 2008Allergan, Inc.Methods for treating a posterior segment of an eye
US20080293637 *May 22, 2008Nov 27, 2008Allergan, Inc.Cross-linked collagen and uses thereof
US20090036403 *Jul 23, 2008Feb 5, 2009Allergan, Inc.Tunably Crosslinked Polysaccharide Compositions
US20090054545 *Sep 15, 2008Feb 26, 2009The General Hospital Corporation Dba Massachusetts Ceneral HospitalAnti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
US20090062249 *Nov 3, 2008Mar 5, 2009Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20090118246 *Oct 23, 2008May 7, 2009Hughes Patrick MTherapeutic ophthalmic compositions containing retinal friendly recpients and related methods
US20090118247 *Oct 24, 2008May 7, 2009Hughes Patrick MTherapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20090143331 *Nov 21, 2008Jun 4, 2009Dimitrios StroumpoulisPolysaccharide gel formulation having increased longevity
US20090143348 *Nov 25, 2008Jun 4, 2009Ahmet TezelPolysaccharide gel compositions and methods for sustained delivery of drugs
US20090148527 *Dec 7, 2007Jun 11, 2009Robinson Michael RIntraocular formulation
US20090156568 *Oct 24, 2008Jun 18, 2009Hughes Partick MTherapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20090197846 *Oct 23, 2008Aug 6, 2009Hughes Patrick MTherapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20090197847 *Oct 24, 2008Aug 6, 2009Hughes Patrick MTherapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20090275614 *Nov 5, 2009David Bar-OrMethylphenidate Derivatives and Uses of Them
US20100004198 *Jan 7, 2010Allergan, Inc.Polysaccharide gel formulation having increased longevity
US20100028437 *Feb 26, 2009Feb 4, 2010Lebreton Pierre FHyaluronic Acid-Based Gels Including Lidocaine
US20100028438 *Feb 26, 2009Feb 4, 2010Lebreton Pierre FHyaluronic Acid-Based Gels Including Lidocaine
US20100098764 *Nov 10, 2009Apr 22, 2010Allergan, Inc.Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20100098772 *Oct 21, 2008Apr 22, 2010Allergan, Inc.Drug delivery systems and methods for treating neovascularization
US20100099623 *Dec 29, 2009Apr 22, 2010Allergan, Inc.Cross-Linked Collagen and Uses Thereof
US20100099624 *Dec 29, 2009Apr 22, 2010Allergan, Inc.Cross-linked collagen and uses thereof
US20100105698 *May 27, 2009Apr 29, 2010Dmi Life Sciences, Inc.Therapeutic Methods and Compounds
US20100278897 *Nov 4, 2010Allergan, Inc.Intraocular bioactive agent delivery system with molecular partitioning system
US20100324005 *Jun 22, 2010Dec 23, 2010Dmi Acquisition Corp.Method for treatment of diseases
US20110077229 *Dec 6, 2010Mar 31, 2011Allergan, Inc.Steroid Containing Drug Delivery Systems
US20110118206 *May 19, 2011Allergan Industrie, SasHyaluronic acid based formulations
US20110171286 *Jan 13, 2010Jul 14, 2011Allergan, Inc.Hyaluronic acid compositions for dermatological use
US20110171306 *Jul 14, 2011David Bar-OrMethods and products for treatment of diseases
US20110171311 *Jul 14, 2011Allergan Industrie, SasStable hydrogel compositions including additives
US20110182966 *Jul 28, 2011Allergan, Inc.Intracameral sustained release therapeutic agent implants
US20110224164 *May 10, 2010Sep 15, 2011Allergan Industrie, SasFluid compositions for improving skin conditions
US20110229574 *Sep 22, 2011Allergan, Inc.Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US20130136780 *Jan 16, 2013May 30, 2013Allergan, Inc.Crosslinked polysaccharide gel compositions for medical and cosmetic applications
DE202006021081U1Jul 12, 2006May 8, 2012Dmi Biosciences, Inc.Produkte zur Behandlung von Krankheiten
EP1986605A2 *Feb 22, 2007Nov 5, 2008Iscience Interventional CorporationApparatus and formulations for suprachoroidal drug delivery
EP1986605A4 *Feb 22, 2007Feb 13, 2013Iscience Interventional CorpApparatus and formulations for suprachoroidal drug delivery
EP2425839A1Jun 22, 2010Mar 7, 2012DMI Acquistion Corp.Method for treatment of diseases
EP2446887A2Jul 12, 2006May 2, 2012DMI Biosciences, Inc.Use of danazol for the treatment of Alzheimer's disease
EP2446888A2Jul 12, 2006May 2, 2012DMI Biosciences, Inc.Use of danazol for the treatment of uveitis
EP2462959A1Jul 12, 2006Jun 13, 2012DMI Biosciences, Inc.Methods and products for treatment of diseases
EP2468282A2Jul 12, 2006Jun 27, 2012DMI Biosciences, Inc.Methods and products for treatment of diseases
EP2468318A1Jul 12, 2006Jun 27, 2012DMI Biosciences, Inc.Methods and products for treatment of diseases
EP2554170A1Jun 22, 2010Feb 6, 2013DMI Acquistion Corp.Method for treatment of diseases
EP2554171A1Jun 22, 2010Feb 6, 2013DMI Acquistion Corp.Method for treatment of diseases
EP2554172A1Jun 22, 2010Feb 6, 2013DMI Acquistion Corp.Method for treatment of diseases
EP2554173A1Jun 22, 2010Feb 6, 2013DMI Acquistion Corp.Method for treatment of diseases
EP2554174A1Jun 22, 2010Feb 6, 2013DMI Acquistion Corp.Method for treatment of diseases
WO2007047607A2Oct 17, 2006Apr 26, 2007Allergan, Inc.Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
WO2007047607A3 *Oct 17, 2006Nov 15, 2007Allergan IncOcular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
WO2007100745A2Feb 22, 2007Sep 7, 2007Iscience Interventional CorporationApparatus and formulations for suprachoroidal drug delivery
WO2008070402A2 *Nov 9, 2007Jun 12, 2008Allergan, Inc.Intraocular drug delivery systems
WO2008070402A3 *Nov 9, 2007Oct 2, 2008Allergan IncIntraocular drug delivery systems
WO2009039262A2 *Sep 18, 2008Mar 26, 2009Allergan, Inc.Steroid containing ophthalmic drug delivery systems
WO2009039262A3 *Sep 18, 2008May 7, 2009Allergan IncSteroid containing ophthalmic drug delivery systems
WO2010106313A1 *Mar 15, 2010Sep 23, 2010University Of StrathclydeImprovement in solubility of drugs by means of hyaluronic acid
WO2011075481A1Dec 14, 2010Jun 23, 2011Allergan, Inc.Intracameral devices for sustained delivery
WO2012087443A1 *Nov 9, 2011Jun 28, 2012Dow Pharmaceutical Sciences, Inc.Pharmaceutical formulations containing corticosteroids for topical administration
WO2015142853A1 *Mar 17, 2015Sep 24, 2015Encompass Development, Inc.Ocular formulations
Classifications
U.S. Classification514/179
International ClassificationA61K47/36, A61K9/00, A61K31/573
Cooperative ClassificationA61K47/36, A61K9/0048, A61K31/573, A61K31/58
European ClassificationA61K31/573, A61K9/00M16, A61K47/36
Legal Events
DateCodeEventDescription
Oct 14, 2004ASAssignment
Owner name: ALLERGAN, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LYONS, ROBERT T.;CHANG, JAMES N.;TROGDEN, JOHN T.;AND OTHERS;REEL/FRAME:015903/0811
Effective date: 20041011